tiprankstipranks
Advertisement
Advertisement
Coya Therapeutics Updates Q1 Results, COYA 302 Progress
PremiumCompany AnnouncementsCoya Therapeutics Updates Q1 Results, COYA 302 Progress
2M ago
Coya Therapeutics granted FDA Fast Track Designation for COYA 302
Premium
The Fly
Coya Therapeutics granted FDA Fast Track Designation for COYA 302
2M ago
Coya Therapeutics reports Q1 EPS (32c), consensus (39c)
Premium
The Fly
Coya Therapeutics reports Q1 EPS (32c), consensus (39c)
2M ago
Coya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating
PremiumRatingsCoya Therapeutics: Advancing Treg-Focused Pipeline with Near-Term Catalysts in ALS and FTD Supporting Buy Rating
4M ago
Coya publishes study showing reduction in regulatory T cell function in FTD
Premium
The Fly
Coya publishes study showing reduction in regulatory T cell function in FTD
4M ago
Aggressive Treg-Modulating Immunology Strategy and Advancing Clinical Execution Underpin Buy Rating on Coya in ALS and FTD
Premium
Ratings
Aggressive Treg-Modulating Immunology Strategy and Advancing Clinical Execution Underpin Buy Rating on Coya in ALS and FTD
4M ago
Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating
PremiumRatingsCoya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating
7M ago
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data
Premium
Company Announcements
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data
7M ago
Coya Therapeutics announces FDA acceptance of COYA 302 IND application
Premium
The Fly
Coya Therapeutics announces FDA acceptance of COYA 302 IND application
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100